Terms and Conditions The OPENINGS® Program savings card is provided by Alcon. The savings card provides savings on out-of-pocket expenses for up to a 90-day supply of TRAVATAN Z® Solution, SIMBRINZA® Suspension and/or AZOPT® Suspension, as described below. If you have valid prescriptions for more than one product, the copay expense and savings apply to each product. You may use the savings card once every 30, 60, or 90 days, depending on when you last received a 30-, 60-, or 90-day supply of each Alcon product. Use of the savings card does not obligate you to use or to continue using any Alcon product. You may use the savings card at any participating pharmacy located in the United States.
The OPENINGS® Program savings card may not be combined with any savings, discount, free trial, or other similar offer for the same prescription. The savings card is not transferable and is void if reproduced. The savings card is not health insurance. Limit 1 savings card per patient. The OPENINGS® Program savings card has no cash value. Please visit Alcon’s website for our privacy practices. Alcon reserves the right to revoke or amend this offer without notice at any time and to deny payment for noncompliance with the terms of this offer. This offer expires June 30, 2017, unless this offer is earlier terminated by Alcon.
Use of this savings card is subject to applicable state and federal law, and is void where prohibited. In the event an A rated generic equivalent product becomes available for one of the products covered by this savings card, this offer will become void in Massachusetts with respect to that product.
Eligibility By using the OPENINGS® Program savings card, you acknowledge that you currently meet the following eligibility criteria:
Minimum out-of-pocket expenses and maximum coverage amounts Eligible commercially insured patients are responsible for paying out-of-pocket expenses noted below and any amount that exceeds the Alcon payment for each prescription, as follows:
Offer is good for up to 12 bottles each of TRAVATAN Z® Solution, SIMBRINZA® Suspension, and/or AZOPT® Suspension for a single patient. No other purchase necessary.
TRAVATAN® Z Solution is available in 2.5 mL and 5 mL, SIMBRINZA® Suspension is available in 8 mL and AZOPT® Suspension is available in 10 mL and 15 mL bottles. Unless the patient’s health insurer requires that a particular-sized bottle be used, patients may use any combination of bottles to satisfy the 30-, 60- and 90-day quantities.
This offer may be subject to limitations imposed by state or federal law, or by your health insurer. The OPENINGS® Program savings card is not valid where prohibited by law or by your health insurer.
Patient instructions: You must call (866) 972-3008 or visit openingsprogram.com/join to activate your program savings card. Then present the OPENINGS® Program savings card to your pharmacist along with an eligible prescription for TRAVATAN Z® Solution, SIMBRINZA® Suspension, and/or AZOPT® Suspension each time you fill your prescription. The prescriber ID# must be identified on the prescription. When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions and that you will comply with them. You may not use this card if prohibited by your insurer. You are responsible for any reporting of the use of this card required by your insurer. If you have any questions, please call the OPENINGS® Program at (866) 972-3008.
Pharmacist Instructions: Pharmacist Instructions: When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, government-run or government sponsored health care program with a pharmacy benefit. Input card information as secondary coverage and transmit using the COB segment of the NCPDP transaction. Submit transaction to McKesson Corporation using BIN #610524. Acceptable discounts will be displayed in the transaction response. Acceptance of this card and your submission of claims are also subject to the Terms and Condition posted at www.mckesson.com/mprstnc.
For questions regarding setup, claim transmission, patient eligibility or other issues, call the LoyaltyScript® for OPENINGS® Program at 844-236-8027 (8:00 AM-8:00 PM EST, Monday-Friday).
Alcon reserves the right to rescind, revoke or amend this offer at any time.
TRAVATAN Z® Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The recommended dosage is one drop in the affected eye(s) once daily in the evening. TRAVATAN Z® Solution should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect.
TRAVATAN Z® Solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Pigmentation - Travoprost ophthalmic solution has been reported to increase the pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as travoprost is administered. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. The long term effects of increased pigmentation are not known. While treatment with TRAVATAN Z® Solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.
Eyelash Changes - TRAVATAN Z® Solution may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.
Intraocular Inflammation - TRAVATAN Z® Solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.
Macular Edema - Macular edema, including cystoid macular edema, has been reported during treatment with travoprost ophthalmic solution. TRAVATAN Z® Solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Angle-closure, Inflammatory or Neovascular Glaucoma - TRAVATAN Z® Solution has not been evaluated for the treatment of angle-closure, inflammatory or neovascular glaucoma.
Bacterial Keratitis - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial.
Use with Contact Lenses - Contact lenses should be removed prior to instillation of TRAVATAN Z® Solution and may be reinserted 15 minutes following its administration.
The most common adverse reaction observed in controlled clinical studies with TRAVATAN Z® Solution was ocular hyperemia which was reported in 30 to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5 to 10% in these clinical studies included decreased visual acuity, eye discomfort, foreign body sensation, pain and pruritus. In postmarketing use with prostaglandin analogs, periorbital and lid changes including deepening of the eyelid sulcus have been observed.
Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.
Click here for full prescribing information for TRAVATAN Z® Solution.
SIMBRINZA® Suspension is a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
The recommended dose is one drop of SIMBRINZA® Suspension in the affected eye(s) three times daily. Shake well before use. SIMBRINZA® Suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
SIMBRINZA® Suspension is contraindicated in patients who are hypersensitive to any component of this product and neonates and infants under the age of 2 years.
Sulfonamide Hypersensitivity Reactions—Brinzolamide is a sulfonamide, and although administered topically, is absorbed systemically. Sulfonamide attributable adverse reactions may occur. Fatalities have occurred due to severe reactions to sulfonamides. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.
Corneal Endothelium—There is an increased potential for developing corneal edema in patients with low endothelial cell counts.
Severe Hepatic or Renal Impairment (CrCl ≥30 mL/min) — SIMBRINZA® Suspension has not been specifically studied in these patients and is not recommended.
Acute Angle-Closure Glaucoma—The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. SIMBRINZA® Suspension has not been studied in patients with acute angle-closure glaucoma.
Contact Lens Wear—The preservative in SIMBRINZA® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of SIMBRINZA® Suspension but may be reinserted 15 minutes after instillation.
Severe Cardiovascular Disease—Brimonidine tartrate, a component of SIMBRINZA® Suspension, had a less than 5% mean decrease in blood pressure 2 hours after dosing in clinical studies; caution should be exercised in treating patients with severe cardiovascular disease.
Potentiation of Vascular Insufficiency—Brimonidine tartrate, a component of SIMBRINZA® Suspension, may potentiate syndromes associated with vascular insufficiency. It should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Contamination of Topical Ophthalmic Products After Use—There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers have been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
In two clinical trials of 3 months’ duration with SIMBRINZA® Suspension, the most frequent reactions associated with its use occurring in approximately 3-5% of patients in descending order of incidence included: blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, and eye allergy. Adverse reaction rates with SIMBRINZA® Suspension were comparable to those of the individual components. Treatment discontinuation, mainly due to adverse reactions, was reported in 11% of SIMBRINZA® Suspension patients.
In clinical studies of brinzolamide ophthalmic suspension 1%, the most frequently reported adverse events reported in 5-10% of patients were blurred vision and bitter, sour, or unusual taste. Adverse events occurring in 1-5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.
In clinical studies of brimonidine tartrate 0.2%, adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.
Events occurring in approximately 3-9% of the subjects, in descending order, included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision, and muscular pain.
Concomitant administration with oral carbonic anhydrase inhibitors is not recommended due to the potential additive effect. Use with high-dose salicylate may result in acid-base and electrolyte alterations. Use with CNS depressants may result in an additive or potentiating effect. Use with antihypertensives/cardiac glycosides may result in additive or potentiating effect on lowering blood pressure. Use with tricyclic antidepressants may blunt the hypotensive effect of systemic clonidine and it is unknown if use with this class of drugs interferes with IOP lowering. Use with monoamine oxidase inhibitors may result in increased hypotension.
Click here for full prescribing information for SIMBRINZA® Suspension.
AZOPT® Suspension is a carbonic anhydrase inhibitor (CAI) indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The recommended dose is one drop of AZOPT® Suspension in the affected eye(s) three times daily. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten (10) minutes apart.
AZOPT® Suspension is contraindicated in patients who are hypersensitive to any component of this product.
Sulfonamide Hypersensitivity Reactions - AZOPT® Suspension is a sulfonamide and although administered topically it is absorbed systemically. The same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of AZOPT® Suspension. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides. Sensitization may recur when a sulfonamide is re-administered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use.
Corneal Endothelium - Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. There is an increased potential for developing corneal edema in patients with low endothelial cell counts. Caution should be used when prescribing AZOPT® Suspension to this group of patients.
Severe Renal Impairment - AZOPT® Suspension has not been studied in patients with severe renal impairment (CrCl ≥ 30 mL/min). Because AZOPT® Suspension and its metabolite are excreted predominantly by the kidney, AZOPT® Suspension is not recommended in such patients.
Acute Angle-Closure Glaucoma - The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. AZOPT® Suspension has not been studied in patients with acute angle-closure glaucoma.
Contact Lens Wear - The preservative in AZOPT® Suspension, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation, but may be reinserted 15 minutes after instillation.
In clinical studies of AZOPT® Suspension, the most frequently reported adverse events reported in 5-10% of patients were blurred vision and bitter, sour or unusual taste. Adverse events occurring in 1-5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus and rhinitis.
Oral Carbonic Anhydrase Inhibitors - There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral CAI and AZOPT® Suspension. The concomitant administration of AZOPT® Suspension and oral CAIs is not recommended.
High-Dose Salicylate Therapy - In patients treated with oral CAIs, rare instances of acidbase alterations have occurred with high-dose salicylate therapy. Therefore, the potential for such drug interactions should be considered in patients receiving AZOPT® Suspension.
Click here for full prescribing information for AZOPT® Suspension.